Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
39 hedge funds and large institutions have $9M invested in Hepion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.
368% more call options, than puts
Call options by funds: $538K | Put options by funds: $115K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
5% more funds holding
Funds holding: 37 → 39 (+2)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
25% less capital invested
Capital invested by funds: $11.9M → $9M (-$2.93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$94.5K |
| 2 |
Renaissance Technologies
New York
|
+$68.5K |
| 3 |
VF
Virtu Financial
New York
|
+$68.5K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$67.1K |
| 5 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$65.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AMC
Asset Management Corp
Northbrook,
Illinois
|
-$204K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$76K |
| 3 |
HF
HRT Financial
New York
|
-$53K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$52K |
| 5 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$46K |
HEPA Hedge Fund Activity: Q4 2021 in Review
39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2021, worth a combined $9M — down 25% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HEPA positions and 7 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $94.5K. The largest seller was Asset Management Corp, exiting entirely with an estimated $204K sold.
- 39 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2021, up from 37 in Q3 2021.
- Funds reported $9M of Hepion Pharmaceuticals stock for Q4 2021, down 25% quarter-over-quarter.
- 9 funds opened new Hepion Pharmaceuticals positions in Q4 2021 and 7 closed out, a net change of +2 holders.
- The largest Hepion Pharmaceuticals buyer in Q4 2021 was Bank of New York Mellon, an estimated $94.5K added.
- The largest Hepion Pharmaceuticals seller in Q4 2021 was Asset Management Corp, an estimated $204K sold.
Based on aggregated 13F filings for Q4 2021.